Annonce • Dec 12
Green UK Wholesale Ltd acquired The GP Service (UK) Ltd from Kanabo Group Plc (LSE:KNB). Green UK Wholesale Ltd acquired The GP Service (UK) Ltd from Kanabo Group Plc (LSE:KNB) on December 9, 2025. The consideration for the transaction has been paid in full on completion. The specific terms remain confidential to protect the commercial interests of the operating business.
Green UK Wholesale Ltd completed the acquisition of The GP Service (UK) Ltd from Kanabo Group Plc (LSE:KNB) on December 9, 2025. New Risk • Apr 19
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 35% per year over the past 5 years. Market cap is less than US$10m (UK£1.58m market cap, or US$2.10m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Revenue is less than US$5m (UK£1.1m revenue, or US$1.5m). Annonce • Mar 25
Kanabo Group plc Announces Resignation of Ian Mattioli as Non-Executive Director Kanabo Group PLC announced that Ian Mattioli, Non-Executive Director of the Company, has resigned with immediate effect. Due to health and personal reasons, Ian will spend more time committed to his other business interests and the Board takes the opportunity to thank Ian for his commitment to the Company during his tenure. Annonce • Jan 06
Kanabo Group plc Announces Stepping Down of David Tsur from the Board of Directors, Effective 30 January 2025 Kanabo Group plc announced that Mr. David Tsur will be stepping down from the Board of Directors with effect from 30 January 2025. Mr. Tsur has served as a member of the Board since Admission in early 2021 and held the position of Chairman for more than 2 years. He has been part of the Kanabo journey since 2018. Reported Earnings • Oct 03
First half 2024 earnings released: UK£0.003 loss per share (vs UK£0.003 loss in 1H 2023) First half 2024 results: UK£0.003 loss per share (in line with 1H 2023). Revenue: UK£694.0k (up 55% from 1H 2023). Net loss: UK£1.75m (loss widened 13% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 58% per year, which means it is performing significantly worse than earnings. New Risk • Oct 01
New major risk - Revenue and earnings growth Earnings have declined by 36% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£2.4m free cash flow). Earnings have declined by 36% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Revenue is less than US$5m (UK£1.1m revenue, or US$1.5m). Market cap is less than US$100m (UK£7.91m market cap, or US$10.5m). New Risk • Aug 02
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: UK£7.59m (US$9.72m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (UK£7.59m market cap, or US$9.72m). Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Revenue is less than US$5m (UK£895k revenue, or US$1.1m). Annonce • Jun 02
Kanabo Group Plc, Annual General Meeting, Jun 27, 2024 Kanabo Group Plc, Annual General Meeting, Jun 27, 2024. Location: 6th floor, saddlers house, 44 gutter lane, ec2v 6br, london United Kingdom New Risk • May 26
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Revenue is less than US$5m (UK£895k revenue, or US$1.1m). Market cap is less than US$100m (UK£10.1m market cap, or US$12.9m). Reported Earnings • May 01
Full year 2023 earnings released: UK£0.015 loss per share (vs UK£0.017 loss in FY 2022) Full year 2023 results: UK£0.015 loss per share. Revenue: UK£895.0k (up 48% from FY 2022). Net loss: UK£7.99m (loss widened 16% from FY 2022). New Risk • Apr 16
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (50% increase in shares outstanding). Revenue is less than US$5m (UK£813k revenue, or US$1.0m). Market cap is less than US$100m (UK£11.4m market cap, or US$14.2m). New Risk • Nov 02
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: UK£8.06m (US$9.82m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (UK£813k revenue, or US$990k). Market cap is less than US$10m (UK£8.06m market cap, or US$9.82m). Minor Risk Shareholders have been diluted in the past year (50% increase in shares outstanding). Reported Earnings • Oct 02
First half 2023 earnings released: UK£0.003 loss per share (vs UK£0.009 loss in 1H 2022) First half 2023 results: UK£0.003 loss per share (improved from UK£0.009 loss in 1H 2022). Net loss: UK£1.56m (loss narrowed 59% from 1H 2022). New Risk • Jun 11
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: UK£7.82m (US$9.84m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (UK£603k revenue, or US$758k). Market cap is less than US$10m (UK£7.82m market cap, or US$9.84m). Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Annonce • May 11
Kanabo Group Plc has completed a Follow-on Equity Offering in the amount of £0.2 million. Kanabo Group Plc has completed a Follow-on Equity Offering in the amount of £0.2 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 6,944,446
Price\Range: £0.0288 Reported Earnings • May 07
Full year 2022 earnings released: UK£0.016 loss per share (vs UK£0.014 loss in FY 2021) Full year 2022 results: UK£0.016 loss per share (further deteriorated from UK£0.014 loss in FY 2021). Net loss: UK£6.87m (loss widened 51% from FY 2021). Annonce • May 05
Kanabo Group plc Announces Executive Changes Kanabo Group Plc announced the appointment of Sharon Malka as Non-Executive Director (NED) with immediate effect. The company also announced that Gil Efron will step down from his position as a Non-Executive Director with immediate effect, in order to focus on his rehabilitation following a recent accident. Sharon Malkawill assume the role of Chair of the Audit Committee following Gil's departure. Sharon Malka brings a wealth of experience to Kanabo, having held senior leadership positions with a number of international healthcare and technology companies. Sharon Malka is currently Chief Executive Officer of Dotz Nano Ltd. In addition to his position at Dotz, Sharon Malka has spent the past 16 years at MediWound Limited. Sharon is a member of MediWound Limited's Board of Directors, and he has previously been MediWound Limited's Chief Financial Officer and Chief Executive Officer. Previously, Sharon held the role of Partner at Variance Economic Consulting Ltd. and served as a Senior Manager position for PwC Corporate Finance. Sharon Malka is a qualified accountant and holds a B.Sc. in Business Administration from the Business Management College in Israel and an M.B.A. from Bar Ilan University, Israel. Annonce • Jan 18
Kanabo Group Plc Announces Launch of Two New Medical Cannabis Products and Testing of the New it Cannabis Platform Kanabo Group Plc announced the launch of two new medical cannabis extract formulas for inhalation, designed specifically to fill a gap in the market for premium products for patients with severe pain. The new formulas, available in versions suitable for day and evening use, will be branded as a Kanabo-Noidecs partnership with LYPHE Group and used with the VapePod, containing high levels of THC, low CBD, and cannabis naturally derived terpenes. The launch will broaden Kanabo's vape offering to the market and is an additional step for the company to build a robust product offering to all eligible patients in the UK. These new formulas will be available from next week to eligible patients via Dispensary Green pharmacy. Further to the above, Kanabo Group is committed to increasing patient access to prescribed medical cannabis in the UK by developing a new platform using its recently acquired UK subsidiary, The GP Service Ltd. The company announced that all the regulatory approvals have been obtained, and the testing stage of the platform has begun. Additional updates will be provided in due course. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Andy Morrison was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 
